ABSTRACT
Human Papillomavirus (HPV), a prevalent sexually transmitted infection, comprises high-risk (HR-HPV) and low-risk (LR-HPV) viruses, the former posing a high risk for developing malignancies whereas the latter mainly for benign warts. Despite increasing awareness of HPV's impact on men's health, the influence of HR-HPV and LR-HPV urogenital infections on male fertility potential remains uncertain. This study aimed to investigate whether male urogenital infection with HR- or LR-HPV associates with impaired sperm quality, oxidative stress, and inflammation. A total of 205 male patients attending an urology clinic were enrolled. Semen samples were analyzed for HPV using PCR and genotyped by RFLP. Semen quality was evaluated following WHO guidelines. Semen leukocytes, reactive oxygen species (ROS), and sperm viability were analyzed using flow cytometry. HPV was detected in 19% (39/205) of semen samples. HR-HPV infections were more prevalent, with HPV-16 being the most frequent genotype. Neither HR-HPV nor LR-HPV were associated with significant alterations in routine sperm quality parameters. However, HR-HPV+ individuals showed significantly higher levels of sperm necrosis and exhibited increased proportions of ROS+ spermatozoa compared to LR-HPV+ or control individuals. Furthermore, no significant semen inflammation was detected in patients infected with either HR-HPV or LR-HPV, and unexpectedly reduced semen leukocytes and inflammatory cytokines (IL-6 and IL-1ß) were observed in HR-HPV+ patients compared to controls. These observations underscore the importance of comprehensive HPV screening, including genotyping, in urology and fertility clinics to understand the progression of the infection, potential adverse effects on reproductive health, and the oncogenic risks involved.
Subject(s)
Papillomaviridae , Papillomavirus Infections , Semen Analysis , Semen , Spermatozoa , Humans , Male , Papillomavirus Infections/virology , Adult , Spermatozoa/virology , Semen/virology , Papillomaviridae/genetics , Middle Aged , Reactive Oxygen Species/metabolism , Genotype , Young Adult , Inflammation , Oxidative Stress , Genitalia, Male/virology , Adolescent , Cytokines/metabolismABSTRACT
Introduction: Active surveillance (AS) is increasingly recognized as an appropriate strategy for selected patients with papillary thyroid microcarcinomas (PTMC). However, some factors, including physician-related ones, hinder its widespread adoption. Methods: To explore the prevailing barriers and the impact of information on attitudes towards AS implementation, we developed a questionnaire that was completed before and after reading a simple information leaflet by 317 doctors working in different work environments. This leaflet provides information about the overdiagnosis of PTMC, the concept of AS, results of early studies, and main advantages and disadvantages of AS. Results: We observed a greater resistance to AS among male physicians who were more likely to maintain the initial recommendation for surgery or referral to a head and neck surgeon than female physicians (77 % vs. 46 %, p = 0.01), regardless of their medical specialty. Fear of disease progression and of the patient losing follow-up were the main concerns. Reading the educational material significantly increased the number of physicians who endorsed AS as an initial approach to PTMC without risk factors from 14 % to 34 % (p < 0,001). This change in attitude was even more significant when doctors were confronted with a case of PTMC in an elderly patient. Gender, medical specialty, age range and academic environment were the factors that were determinants on the influence of the informative leaflet on the decision-making. The leaflet also increased the number of doctors who considered themselves capable of dealing with this patient profile; however, 17 % declared that the place where they worked would not be able to meet the need for periodic assessments and necessary examinations. This was particularly true for the 20 % of the professionals working in rural areas. Conclusion: A simple educational leaflet with basic information presented via social media increased the number of Brazilian physicians who endorsed AS for PTMC management and proved to be a facilitating tool for understanding and accepting it. Our results suggest that this method can be easily extended to larger population.
ABSTRACT
RESUMEN Antecedentes: el tratamiento del carcinoma diferenciado de tiroides (CDT) de bajo riesgo es aún motivo de discusión. En las últimas décadas se observó una migración hacia tratamientos personalizados acordes con las características de cada paciente y de cada tumor. Las guías de práctica vigentes habilitan la lobectomía en pacientes seleccionados, con bajo riesgo de recurrencia. Objetivo: describir los resultados en una cohorte de pacientes con CDT de bajo riesgo de recurrencia tratados con lobectomía tiroidea. Material y métodos: estudio observacional descriptivo de una revisión retrospectiva de historias clínicas de 114 pacientes con CDT tratados con lobectomía tiroidea entre enero de 2015 y abril de 2023. Resultados: fueron operados 114 pacientes, con media de edad de 44 años ± 12; 90 (79%) fueron mujeres. La mediana del tamaño tumoral fue de 9,4 mm, RIC (rango intercuartílico 25-75% 7-13 mm), y 103 de los nódulos (90%) fueron ecográficamente sólidos. Solo 2 pacientes con invasión vascular mayor de 4 vasos requirieron completar la tiroidectomía total. No se registraron complicaciones de importancia, salvo una parálisis recurrencial transitoria. Con un seguimiento promedio de 33,4 meses, no se observaron recurrencias locorregionales ni a distancia en la población analizada. Conclusión: la lobectomía tiroidea en el tratamiento del CDT de bajo riesgo tuvo una baja morbilidad sin recurrencias en la serie presentada. La selección rigurosa de los pacientes y la interacción de un equipo multidisciplinario se consideran esenciales para la implementación exitosa de esta metodología terapéutica.
ABSTRACT Background: The treatment of low-risk differentiated thyroid cancer (DTC) is still a matter of debate. Over the past few decades, there has been a shift towards a more personalized approach, tailored to the individual risks of each patient and tumor. The current practice guidelines recommend lobectomy in selected patients, with low risk of recurrence. Objective: To describe the results of thyroid lobectomy in a cohort of patients with DTC with low risk of recurrence. Material and methods: We conducted a descriptive and observational study. The medical records of patients with DTC who underwent thyroid lobectomy between January 2015 and April 2023 were retrospectively reviewed. Results: A total of 114 patients were operated on; mean age was 44 ± 12 years and 90 (79%) were women. The median tumor size was 9.4 mm (IQR 25-75% 7-13 mm), and 103 nodules (90%) were solid on ultrasound. Only 2 patients with vascular invasion involving > 4 vessels required completion thyroidectomy. There were no major complications and only one patient developed temporary recurrent laryngeal palsy. There were no locoregional or distant recurrences during mean follow-up of 33.4 months. Conclusion: Thyroid lobectomy for low-risk DTC had low morbidity and no recurrences in the series presented. The rigorous selection of patients and the interaction of a multidisciplinary team are considered essential for the successful implementation of this therapeutic approach.
ABSTRACT
Active Surveillance is a non-invasive strategy designed to identify a minority of patients with low-risk papillary thyroid carcinoma who might experience clinical progression and benefit from additional definitive treatments. Global experience suggests that these tumors typically show minimal changes in size during active surveillance, often demonstrating very slow growth or even size reduction. Moreover, the rate of lymph node metastases is low and can be effectively managed through rescue surgery, without impacting cancer-related mortality. However, despite 30 years of experience demonstrating the safety and feasibility of active surveillance for appropriately selected patients, this approach seems to have limited adoption in specific contexts. This limitation can be attributed to various barriers, including disparities in access to accurate information about the indolent nature of this disease and the prevalence of a maximalist mindset among certain patients and medical settings. This review aims to revisit the experience from the last three decades, provide current insights into the clinical outcomes of active surveillance trials, and propose a systematic approach for its implementation. Furthermore, it intends to emphasize the importance of precise patient selection and provides new perspectives in the field.
Subject(s)
Carcinoma, Papillary , Thyroid Neoplasms , Humans , Thyroidectomy , Watchful Waiting , Carcinoma, Papillary/pathology , Thyroid Neoplasms/epidemiologyABSTRACT
PURPOSE: Assess the local recurrence rate and global survival rate among women diagnosed with breast cancer who underwent intraoperative electron radiotherapy (IOERT) between 2007 and 2017, in a single private healthcare setting in Belo Horizonte, Brazil. MATERIAL AND METHODS: This is a retrospective study based on medical records about the outcomes of patients submitted to breast-conserving surgery followed by IOERT. The collected variables included the patient's profile and tumor features, IOERT isodose, and outcomes. The quantitative data were presented in tables of frequency. The survival curves were created with the Kaplan-Meier method. In all tests, the adopted relevance level was 5%. The analyses were carried out with SPSS version 25.0. RESULTS AND CONCLUSIONS: The samples consisted of 78 patients, among which a total of 14 (17.9%) recurrences were observed. The median time of recurrence was 49 months after the IOERT was performed. Of the 78 patients analyzed, 13 (16.7%) died, 5 (6.4%) of which were due to breast cancer. The global survival rate in 5 years was 94.9% and 90.4% in 10 years. The local recurrence rate in 5 years was 89.7% and 86.4% in 10 years. Our findings revealed a higher local recurrence rate than the literature data. However, our results also showed that patients classified as low-risk had an overall survival of 5 and 10 years similar to other studies in the literature, reaffirming that low-risk women can benefit from IOERT. Given this finding, it is reaffirmed that rigorous eligibility criteria for IOERT are critical to reducing local recurrence.
Subject(s)
Breast Neoplasms , Humans , Female , Brazil/epidemiology , Retrospective Studies , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Mastectomy, Segmental/methods , Radiotherapy Dosage , Combined Modality TherapyABSTRACT
Objetivo: Identificar as evidências científicas sobre os benefícios do uso da bola suíça em gestantes na assistência ao parto de baixo risco. Métodos: Revisão integrativa da literatura, realizada nas bases de dados Medline/PubMed, LILACS via BVS e biblioteca Scielo para responder à questão norteadora: Quais os benefícios do uso da bola suíça em gestantes na assistência ao parto de baixo risco? As buscas ocorreram entre março e abril de 2022, utilizando os descritores "gestantes", "terapia por exercício", "trabalho de parto", "parto normal". Após os cruzamentos desses descritores, identificaram-se 230 artigos, que ao aplicar os critérios de elegibilidade, restaram dez estudos, avaliados e elegíveis para a revisão. Na extração dos dados elaborou-se um instrumento para coleta. Resultados: 10 estudos foram elegíveis após seleção. Destes, a maior parte (8) desenvolvidos no Brasil (1) China e (1) em Taiwan. O periódico de maior frequência das publicações foi Acta Paulista de Enfermagem (3). Quanto ao ano de publicação o ano com menos publicações foi 2012 (1), seguido 2013 (2), 2019 (2). Quanto ao delineamento o tipo ensaio clinico prevaleceu nas publicações (5). Conclusão: esta revisão aponta benefícios do uso da bola suíça como instrumento de trabalho que pode favorecer a assistência ao parto de baixo risco evidenciando ser uma alternativa viável para profissionais nesse campo de atuação.(AU)
To identify the scientific evidence on the benefits of using the Swiss ball in pregnant women in low-risk childbirth care. Methods: Integrative literature review, carried out in Medline/PubMed, LILACS via VHL and Scielo library databases to answer the guiding question: What are the benefits of using the Swiss ball in pregnant women in low-risk childbirth care? The searches took place between March and April 2022, using the descriptors "pregnant women", "exercise therapy", "labor", "normal delivery". After crossing these descriptors, 230 articles were identified, which, when applying the eligibility criteria, left ten studies, evaluated and eligible for the review. In the data extraction, a collection instrument was elaborated. Results: 10 studies were eligible after selection. Of these, most (8) developed in Brazil (1) China and (1) Taiwan. The journal with the highest frequency of publications was Acta Paulista de Enfermagem (3). As for the year of publication, the year with the fewest publications was 2012 (1), followed by 2013 (2), 2019 (2). As for the design, the clinical trial type prevailed in the publications (5). Conclusion: this review points out the benefits of using the Swiss ball as a work tool that can favor low-risk childbirth care, showing that it is a viable alternative for professionals in this field.(AU)
Objetivo: Identificar la evidencia científica sobre los beneficios del uso del balón suizo para gestantes en la atención al parto de bajo riesgo. Métodos: Revisión bibliográfica integradora, realizada en las bases de datos Medline/PubMed, LILACS vía BVS y biblioteca Scielo para responder a la pregunta guía: ¿Cuáles son los beneficios del uso del balón suizo para gestantes en la atención al parto de bajo riesgo? Las búsquedas se realizaron entre marzo y abril de 2022, utilizando los descriptores "pregnant women", "exercise therapy", "labour", "normal delivery". Tras cruzar estos descriptores, se identificaron 230 artículos y, una vez aplicados los criterios de elegibilidad, quedaron diez estudios, que fueron evaluados y elegibles para la revisión. Para extraer los datos, se elaboró una herramienta de recogida de datos. Resultados: Tras la selección, 10 estudios fueron elegibles. De ellos, la mayoría (8) se realizaron en Brasil (1) China y (1) Taiwán. La revista más frecuentemente publicada fue Acta Paulista de Enfermagem (3). En cuanto al año de publicación, el año con menos publicaciones fue 2012 (1), seguido de 2013 (2), 2019 (2). En cuanto al diseño, el tipo de ensayo clínico prevaleció en las publicaciones (5). Conclusión: Esta revisión señala los beneficios del uso del balón suizo como herramienta de trabajo que puede favorecer la atención al parto de bajo riesgo, mostrándose como una alternativa viable para los profesionales de este ámbito.(AU)
Subject(s)
Female , Pregnancy , Labor, Obstetric , Parturition , Pregnant Women , MidwiferyABSTRACT
High-risk human papillomavirus (HPV) is etiologically related to cervical cancer, other anogenital cancers and oropharyngeal carcinomas. Low-risk HPV, especially HPV6 and HPV11, cause genital warts and laryngeal papillomas. However, the accumulating data suggests that HPV6 and HPV11 may cause malignant lesions at non-cervical anatomic sites. This review aims to estimate the proportions of single and dual HPV6/11 infections in multiple cancers reported in the last 10 years in the Cochrane, Embasa and PubMed databases. Secondly, the genomes of HPV6/11 were compared with the most common high-risk genotype, HPV16, to determine the similarities and differences. A total of 11 articles were selected, including between one and 334 HPV+ cancer patients. The frequencies of single or dual HPV6/11 infections ranged between 0-5.5% for penile and 0-87.5% for laryngeal cancers and were null for vulvar, vaginal and oral cancers. The genomic similarities between HPV6/11 and HPV16 mainly involved the E7 gene, indicating a limited ability to block cell differentiation. The presence of single or dual HPV6/11 infections in variable proportions of penile and laryngeal cancers support the vaccination strategies that cover these genotypes, not only for preventing genital warts but also for cancer prevention. Other risk factors and co-carcinogens are likely to participate in epithelial carcinogenesis associated with low-risk HPV.
ABSTRACT
Infection of epithelial cells with high-risk HPV (HR-HPV) types, followed by expression of virus oncogenic proteins (E5, E6, and E7), leads to genomic imbalance, suppression of tumor inhibitors, and induction of oncogenes. Low-risk HPV (LR-HPV) may slow the rate at which cervical cancer spreads to an invasive stage since co-infection with LR-HPV is linked to a decreased risk of future invasive cancer than infection with HR-HPV alone. We then propose that cancer-progressing changes may be distinguished through identifying the functional differences between LR-HPV and HR-HPV. Lentiviral strategies were followed to establish HaCaT cells with constitutive expression of HPV oncogenes. RNAseq experiments were designed to analyze the transcriptome modulations caused by each of the E5, E6, and E7 oncogenes of HPV-16 and HPV-84 in HaCaT cells. We identified enhanced RNA degradation, spliceosome, and RNA polymerase pathways related to mRNA processing. ATTS (alternative transcription termination site) was discovered to be more prevalent in cells with HPV-16E5 than HPV-84E5. In HPV-16E6-infected cells, ATTS gain was significantly higher than ATTS loss. Cells with HPV-16E7 had more isoforms with intron retention (IR) than those with HPV-84E7. We identified switches in ADAM10, CLSPN, and RNPS1 that led to greater expression of the coding isoforms in HR-HPV. The results of this work highlight differences between LR-HPV and HR-HPV in mRNA processing. Moreover, crucial cervical cancer-related switch events were detected.
Subject(s)
Oncogene Proteins, Viral , Papillomavirus Infections , Uterine Cervical Neoplasms , Female , Humans , Uterine Cervical Neoplasms/pathology , Human papillomavirus 16/genetics , Human papillomavirus 16/metabolism , Papillomavirus Infections/genetics , Oncogene Proteins, Viral/genetics , Oncogene Proteins, Viral/metabolism , Oncogenes , Papillomavirus E7 Proteins/genetics , Keratinocytes/metabolism , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/genetics , Papillomaviridae/genetics , Papillomaviridae/metabolism , Adaptor Proteins, Signal Transducing/metabolismABSTRACT
Reducing the recurrence rate in patients with low-risk non-muscle invasive bladder cancer patients is a critical concern in the urologic community. The gold standard treatment is single instillation (SI) of intravesical chemotherapy after transurethral resection of bladder tumor (TURBT), but unfortunately, it is underused. Continuous bladder irrigation (CBI) after TURBT is an alternative strategy to SI for the prevention of bladder tumor implantation and recurrence. The aim of this review was to present the evidence that supports CBI after TURBT when SI is not possible.
ABSTRACT
The detection of low-risk thyroid carcinoma has increased in recent decades, although disease-specific mortality remained without changes. The high prevalence of occult carcinomas in autopsy studies, and hence the underlying indolent course of this entity, prompted the emergence of active surveillance as an alternative approach to these tumors. This strategy aims to recognize the minority group of patients who will develop clinical progression and probably benefit from deferred surgery. Experience around the world has shown that during active surveillance these tumors are mostly unchanged in size, with very-slow growth and even a decrease in diameter. Moreover, the rates of lymph node metastases were low and easily handled by rescue surgery, and distant metastases have not been reported. Given the high prevalence of small thyroid carcinomas and the excellent outcomes for observation, active surveillance provides a safe and feasible alternative in properly selected patients with low-risk thyroid cancer.
ABSTRACT
BACKGROUND: In patients with low-risk differentiated thyroid cancer (DTC), remnant ablation with radioiodine (RA) after total thyroidectomy (TT) is controversial. No benefits have been demonstrated in terms of mortality or disease-free survival. Recent evidence found that RA did not improve mid-term outcomes. PURPOSE: To evaluate initial response to treatment and long-term follow-up status in low-risk DTC patients after TT vs. TT + RA with 131I 1.11 GBq (30 mCi). METHODS: Prospective multicenter non-randomized study; 174 low-risk DTC that underwent TT were recruited an divided in two groups according to RA (87 ablated and 87 non-ablated). Response to treatment was evaluated at 6-18 months after thyroidectomy and at the end of follow-up with measurements of thyroglobulin, and anti-thyroglobulin antibodies levels, and neck ultrasonography. RESULTS: Baseline characteristics of both groups were similar. Ablated patients: median age 45.5 years, 84% females, 95.4% papillary thyroid carcinoma (PTC), mean tumor size 16 mm; non-ablated: median age 45 years, 88.5% females, 96.6% PTC, mean tumor size 14 mm. Response to initial treatment was similar between both groups, with < 2% of structural incomplete response. Final status was evaluated in 139 cases (median follow-up of 60 months). Among ablated patients, 82.8% had no evidence of disease (NED), 12% had an indeterminate response (IR) and 5% a biochemical incomplete response (BIR). Non-ablated patients had NED in 90%, IR in 8.7% and BIR in 1.2%. No statistical difference was found between groups (p = 0.29). No patient had evidence of structural disease at the end of follow-up. CONCLUSIONS: Our findings support the recommendation against routine RA in low-risk DTC patients.
Subject(s)
Iodine Radioisotopes , Thyroid Neoplasms , Female , Humans , Middle Aged , Male , Iodine Radioisotopes/therapeutic use , Prospective Studies , Follow-Up Studies , Thyroid Neoplasms/radiotherapy , Thyroid Neoplasms/surgery , Thyroid Neoplasms/pathology , Thyroidectomy/methods , Thyroid Cancer, Papillary/radiotherapy , Thyroid Cancer, Papillary/surgery , Treatment Outcome , Retrospective StudiesABSTRACT
RATIONALE: Preoperative care is one of the main areas in which to address low-value care. A detailed definition of what low-value care is in this period of the surgical care journey paves the way for new scientific research, clinical improvements, and reduction of unnecessary costs in this field. AIMS AND OBJECTIVE: To identify how low-value care in low-risk preoperative population has been defined in the scientific literature and propose a low-value care framework with potential consequences in this setting. METHODS: Scoping review of theoretical studies and peer-reviewed papers, including reviews, commentaries, or expert opinions, were considered eligible for inclusion. The following databases were consulted: MEDLINE (via PubMed), EMBASE, and SCOPUS (from inception to July 24, 2021), using a structured search with the keywords "low value care", "clinical waste", "preoperative", and "elective procedures." Two independent reviewers performed study selection and data extraction. The definition of low-value care in the preoperative period and their consequences were described after extracting previous low-value care concepts and summarising the contents. Also, a visual framework was built with this information. RESULTS: From 1519 publications identified in the initial searches, 22 underwent full-text assessment, and 11 conceptual studies were included in the review. A total of four studies (36%) presented a general low-value care definition, and all studies report some situations considered low-value care in the preoperative field of low-risk surgeries. The most common example of preoperative low-value care, listed in nine studies (81%), was having asymptomatic patients undergo screening tests before surgery. The main clinical and nonclinical consequences of low-value care in the preoperative phase included false-positive results from exams as well as psychological distress, increased costs, and delay in surgery. CONCLUSIONS: Revisiting and integrating previous definitions of low-value care in low-risk surgery into a scoping review is a starting point for de-implementing unnecessary care and promoting improvements in surgical pathways.
Subject(s)
Low-Value Care , Preoperative Care , Humans , Preoperative Care/methods , BibliometricsABSTRACT
Abstract Objective There are few multinational studies on gestational trophoblastic neoplasia (GTN) treatment outcomes in South America. The purpose of this study was to assess the clinical presentation, treatment outcomes, and factors associated with chemoresistance in low-risk postmolar GTN treated with first-line single-agent chemotherapy in three South American centers. Methods Multicentric, historical cohort study including women with International Federation of Gynecology and Obstetrics (FIGO)-staged low-risk postmolar GTN attending centers in Argentina, Brazil, and Colombia between 1990 and 2014. Data were obtained on patient characteristics, disease presentation, and treatment response. Logistic regression was used to assess the relationship between clinical factors and resistance to first-line single-agent treatment. A multivariate analysis of the clinical factors significant in univariate analysis was performed. Results A total of 163 women with low-risk GTN were included in the analysis. The overall rate of complete response to first-line chemotherapy was 80% (130/163). The rates of complete response to methotrexate or actinomycin-D as first-line treatment, and actinomycin-D as second-line treatment postmethotrexate failure were 79% (125/157), 83% (⅚), and 70% (23/33), respectively. Switching to second-line treatment due to chemoresistance occurred in 20.2% of cases (33/163). The multivariate analysis demonstrated that patients with a 5 to 6 FIGO risk score were 4.2-fold more likely to develop resistance to first-line single-agent treatment (p= 0.019). Conclusion 1) At presentation, most women showed clinical characteristics favorable to a good outcome, 2) the overall rate of sustained complete remission after first-line single-agent treatment was comparable to that observed in developed countries, 3) a FIGO risk score of 5 or 6 is associated with development of resistance to first-line single-agent chemotherapy.
Resumo Objetivo Existem poucos estudos multinacionais sobre os resultados do tratamento da neoplasia trofoblástica gestacional (NTG) na América do Sul. O objetivo deste estudo foi avaliar a apresentação clínica, os resultados do tratamento e os fatores associados a casos de quimiorresistência em NTG pós-molar de baixo risco tratados com quimioterapia de agente único de primeira linha em três centros sul-americanos. Métodos Estudo multicêntrico de coorte histórica incluindo mulheres com NTG pós-molar de baixo risco com estadiamento International Federation of Gynecology and Obstetrics (FIGO) em centros de atendimento na Argentina, Brasil e Colômbia entre 1990 e 2014. Foram obtidos dados sobre as características do paciente, apresentação da doença e resposta ao tratamento. A regressão logística foi usada para avaliar a relação entre fatores clínicos e resistência ao tratamento de primeira linha com agente único. Foi realizada uma análise multivariada dos fatores clínicos significativos na análise univariada. Resultados Cento e sessenta e três mulheres com NTG de baixo risco foram incluídas na análise. A taxa global de resposta completa à quimioterapia de primeira linha foi de 80% (130/163). As taxas de resposta completa ao metotrexato ou actinomicina-D como tratamento de primeira linha e actinomicina-D como tratamento de segunda linha após falha do metotrexato foram 79% (125/157), 83% (⅚) e 70% (23/33), respectivamente. A mudança para o tratamento de segunda linha por quimiorresistência ocorreu em 20,2% dos casos (33/163). A análise multivariada demonstrou que pacientes com pontuação de risco FIGO de 5 a 6 foram 4,2 vezes mais propensos a desenvolver resistência ao tratamento com agente único de primeira linha (p= 0,019). Conclusão 1) Na apresentação, a maioria das mulheres demonstrou características clínicas favoráveis a um bom resultado, 2) a taxa geral de remissão completa sustentada após o tratamento de primeira linha com agente único foi comparável à de países desenvolvidos, 3) um escore de risco FIGO de 5 ou 6 está associado ao desenvolvimento de resistência à quimioterapia de agente único de primeira linha.
Subject(s)
Humans , Female , Pregnancy , South America , Hydatidiform Mole , Gestational Trophoblastic Disease/therapy , Drug TherapyABSTRACT
BACKGROUND: This study aims to assess the neonatal outcomes related to maternal SARS-COV-2 infection. METHODS: In this study, we identified newborns born between May 14 and August 31, 2020, to mothers who were PCR-SRAS-CoV-2 positive at the time of delivery. From the cohort of 974 infants, we performed a nested case-control study. RESULTS: During the study period, 133 (13.7%) mothers were positive for SARS-CoV-2. Among the 35 pregnant women with COVID-19 symptoms (26.3%), cough was the most common symptom, present in half of the cases. Four of them have progressed to critical pneumonia requiring transfer to intensive care unit. The neonates from mothers with positive SARS-CoV-2-RT-PCR, were routinely tested for COVID-19 within the first 24 h after labor, and 3 other newborns tested in the presence of symptoms. There was no significant difference between the two groups with respect to preterm birth, meconium-stained amniotic fluid distress, and neonatal asphyxia. Most infants were breastfed at birth, regardless of their mothers' COVID-19 status. In COVID-19-positive pregnant women admitted to intensive care unit, the proportion of preterm births (OR=12.5 [1.7-90.5]), fetal death in utero (OR=25.9 [2.2-305]) and admission in neonatal intensive care unit admission (OR=13.4 [3.0-60]), appeared higher than the controls. No maternal deaths were recorded. CONCLUSIONS: Our data suggest little neonatal morbidity associated with maternal COVID-19, except for those born to mothers admitted to intensive care unit. However, under breastfeeding conditions with rigorous hygiene precautions and parental education, the risk of transmission of SARS-COV-2 virus to the newborn was very low.
Subject(s)
COVID-19 , Pregnancy Complications, Infectious , Premature Birth , COVID-19/epidemiology , Case-Control Studies , Female , French Guiana/epidemiology , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/epidemiology , Pregnancy Outcome , Premature Birth/epidemiology , SARS-CoV-2ABSTRACT
BACKGROUND: Cervical cancer (CC) is the fourth most common malignancy of the female genital tract. Human Papillomavirus (HPV) is the main cause of precancerous lesions and CC cases worldwide. OBJECTIVE: We assessed the prevalence and distribution of HPV types and their association with precancerous lesions and CC. METHODS: HPV genotypes were detected by 3 methods depending on the year of in which the sample was analyzed: MY09/11 RFLPs (1997 to 2010), GP5+/6+ primer systems (2005 to 2010) and INNO-LiPA HPV Genotyping Extra (2010 to 2019) in cervical samples (No-IL: 4445; LSIL: 2464; HSILs: 151 and CC: 253) from women from southern Mexico. RESULTS: The overall HPV prevalence was 54.17%, and hpv-16 was the most common genotype. In single infection, the high-risk HPV genotypes (group 1) were associated with squamous intraepitelial lesions (LSIL: HPV-39 (OR = 10.58, 95% CI 4.09-27.36, P < .001); HSIL: HPV-31 (OR = 14.76, 95% CI 6.56-33.20, P < .001); and CC: HPV-16 (OR = 25.01, 95% CI 18.83-33.21, P < .001). In multiple infections, the HPV genotypes (HPV-16 and HPV-18) were also associated with a high risk of lesions [LSIL: HPV-18 (OR = 3.45; 95% CI 1.36-8.91; P = .009); HSIL: HPV-18 (OR = 5.12; 95% CI 1.21-21.68; P = .026); and CC: HPV-16 (OR = 3.03; 95% CI 1.72-5.32; P < .001)] compared to single infection. In the analysis adjusted for age, giving birth, and cigarette smoking, a significant increase in the risk of LSIL, HSIL, and CC was maintained. CONCLUSIONS: This study provides current data on the prevalence and distribution of HPV genotypes in women from southern Mexico, which could serve as a valuable reference to guide nationwide CC screening programs and provide scientific evidence that could be useful for vaccine development efforts. Likewise, it was identified that infection with carcinogenic HPV genotypes is an independent risk factor for LSIL, HSIL, and CC.
Subject(s)
Alphapapillomavirus , Papillomavirus Infections , Precancerous Conditions , Squamous Intraepithelial Lesions , Uterine Cervical Dysplasia , Uterine Cervical Neoplasms , Female , Genotype , Human papillomavirus 16/genetics , Humans , Mexico/epidemiology , Papillomaviridae/genetics , Precancerous Conditions/epidemiology , Pregnancy , Prevalence , Uterine Cervical Neoplasms/pathology , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Dysplasia/pathologyABSTRACT
This work examines a mathematical model of COVID-19 among two subgroups: low-risk and high-risk populations with two preventive measures; non-pharmaceutical interventions including wearing masks, maintaining social distance, and washing hands regularly by the low-risk group. In addition to the interventions mentioned above, high-risk individuals must take extra precaution measures, including telework, avoiding social gathering or public places, etc. to reduce the transmission. Those with underlying chronic diseases and the elderly (ages 60 and above) were classified as high-risk individuals and the rest as low-risk individuals. The parameter values used in this study were estimated using the available data from the Johns Hopkins University on COVID-19 for Brazil and South Africa. We evaluated the effective reproduction number for the two countries and observed how the various parameters affected the effective reproduction number. We also performed numerical simulations and analysis of the model. Susceptible and infectious populations for both low-risk and high-risk individuals were studied in detail. Results were displayed in both graphical and table forms to show the dynamics of each country being studied. We observed that non-pharmaceutical interventions by high-risk individuals significantly reduce infections among only high-risk individuals. In contrast, non-pharmaceutical interventions by low-risk individuals have a significant reduction in infections in both subgroups. Therefore, low-risk individuals' preventive actions have a considerable effect on reducing infections, even among high-risk individuals.
ABSTRACT
OBJECTIVES: While unknown for oropharyngeal squamous cell carcinoma (OPSCC) and oral squamous cell carcinoma (OSCC), some studies assessing cervical carcinoma have shown that human papillomavirus (HPV) co-infection can be associated with its prognosis. METHODS: Through in situ hybridization (HPV and Epstein-Barr virus [EBV] probes) and immunohistochemistry (p16INK4a, cyclin D1, p53, and Ki-67 antibodies), 126 OPSCC and 109 OSCC samples were assessed. RESULTS: All patients were EBV-negative. OPSCC (25%) showed a significant association with HPV compared to OSCC (11%). Almost all HPV-associated cases were p16INK4a-positive. Regarding OPSCC and OSCC, 23 and 7 cases were positive for high-risk HPV (HRHPV) only, 6 and 3 cases for low-risk HPV (LRHPV) only, and 3 and 2 cases for HRHPV/LRHPV, respectively. HPV-associated carcinomas showed a significantly higher proliferative index than HPV-unassociated carcinomas. Both carcinomas showed a similar overall survival rate, which was not affected by the HPV status. However, when comparing HPV-associated subgroups, patients with HRHPV/LRHPV-associated carcinomas showed worse survival. CONCLUSION: LRHPV-associated and HRHPV/LRHPV-associated cases can also be detected when assessing OSCC and OPSCC. Further studies, especially in populations with a high prevalence of HPV-associated OPSCC, are necessary to understand the clinicopathological behavior of these neoplasm subgroups.
Subject(s)
Alphapapillomavirus , Carcinoma, Squamous Cell , Coinfection , Epstein-Barr Virus Infections , Head and Neck Neoplasms , Mouth Neoplasms , Oropharyngeal Neoplasms , Papillomavirus Infections , Carcinoma, Squamous Cell/pathology , Coinfection/complications , Coinfection/epidemiology , Epstein-Barr Virus Infections/complications , Head and Neck Neoplasms/complications , Herpesvirus 4, Human , Humans , Mouth Neoplasms/epidemiology , Oropharyngeal Neoplasms/pathology , Papillomaviridae , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Squamous Cell Carcinoma of Head and Neck/complicationsABSTRACT
Resumen En las últimas décadas, la creciente identificación de nódulos tiroideos ha dado lugar a un incremento dramático en el diagnóstico y tasa de incidencia del cáncer de tiroides, sin embargo, su mortalidad se ha mantenido estable. La mayor fracción de este incremento es atribuible al creciente uso de tecnologías de diagnóstico, que ha identificado un número cada vez mayor de cánceres papilares de tiroides (CPT), en su gran mayoría pequeños y de bajo riesgo clínico. La mayoría de estos tumores no generarán morbilidad o mortalidad a pesar de no ser tratados. La práctica clínica ha evolucionado hacia un tratamiento menos agresivo de los CPTs. La vigilancia activa (VA) ha surgido como una nueva alternativa terapéutica dentro del algoritmo de tratamiento, que tiene como objetivo reconocer a un potencial grupo minoritario de pacientes en quienes sus carcinomas papilares tiroideos sí progresarán clínicamente y, por lo tanto, en ellos un tratamiento quirúrgico resulte en mayor beneficio que perjuicio. En esta revisión nos planteamos como objetivo describir la epidemiología del carcinoma papilar tiroideo, el concepto de vigilancia activa en esta área y los resultados clínicos obtenidos mediante este abordaje terapéutico en las distintas experiencias realizadas en el mundo hasta la fecha.
Abstract In recent decades, the increasing identification of thyroid nodules has led to a dramatic increase in the diagnosis and incidence rate of thyroid cancer. However, their mortality has remained stable. The largest fraction of this increase is attributable to the growing use of diagnostic technologies, which has identified an increasing number of mostly small, low clinical risk papillary thyroid cancers (PTC). Most of these tumors will not generate morbidity or mortality despite being untreated. Clinical practice has evolved towards a less aggressive treatment of PTC's. Active surveillance (AS) has emerged as a new therapeutic alternative within the treatment algorithm, which aims to recognize a potential minority group of patients in whom their thyroid papillary carcinoma will progress clinically, and therefore in whom surgical treatment will result in greater benefit than harm. In this review we aim to describe the epidemiology of papillary thyroid carcinoma, the concept of active surveillance in this area and the clinical results obtained by this therapeutic approach in the different experiences carried out in the world until now.